There are 1076 resources available
48P - Clinical characteristics of patients (pts) with HER2+ unresectable (u) or metastatic (m) breast cancer (BC): HER2 REAL Asia cohort
Presenter: Soo Chin Lee
Session: Poster Display session
Resources:
Abstract
49P - Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer patients
Presenter: Yen-Shen Lu
Session: Poster Display session
Resources:
Abstract
50P - Establishment and validation of a predictive model for the risk and prognosis of bone metastasis in breast cancer: Research based on provincial hospital data in China
Presenter: Lin Miao
Session: Poster Display session
Resources:
Abstract
51P - Taxane-based chemotherapy versus endocrine therapy plus CDK4/6 inhibitor as first-line treatment in hormone receptor-positive HER2-negative metastatic breast cancer that progressed on adjuvant endocrine therapy
Presenter: Yang YUAN
Session: Poster Display session
Resources:
Abstract
52P - Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer with distinct IHC statuses: Evidence from a Chinese population
Presenter: Song Wu
Session: Poster Display session
Resources:
Abstract
53P - Real-world treatment patterns for HER2+ and HR+/HER2- advanced breast cancer in county areas of China
Presenter: Yinghua Ji
Session: Poster Display session
Resources:
Abstract
55P - A retrospective study to investigate the prevalence and describe the treatment outcomes of HER2-low unresectable and/or metastatic breast cancer in Taiwan: The RetroBC-HER2L-TW study
Presenter: Chih-Yi Hsu
Session: Poster Display session
Resources:
Abstract
56P - Palbociclib versus ribociclib in first-line therapy of patients with metastatic breast cancer: Direct comparison in real-world practice
Presenter: Elena Tsareva
Session: Poster Display session
Resources:
Abstract
62P - Patient satisfaction and preference for atezolizumab subcutaneous (atezo SC) by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002
Presenter: Busyamas Chewaskulyong
Session: Poster Display session
Resources:
Abstract
63P - A randomised, double-blind, phase I study to compare the pharmacokinetics, safety, tolerability, and immunogenicity of HLX15 and daratumumab in healthy male participants
Presenter: Yu-wen Su
Session: Poster Display session
Resources:
Abstract